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Background
Although the importance of DNA vaccines, especially as a
priming immunization has been well established in
numerous HIV vaccine studies, the immunogenicity of
DNA vaccines is generally moderate. Novel adjuvant is in
urgent need for improving the immunogenicity of DNA
vaccine.  Mycobacterium bovis bacillus Calmette-Guérin
(BCG) cell-wall skeleton and nuclear acid which can acti-
vate at least five kinds of TLRs (TLR1, TLR2, TLR4, TLR6
and TLR9).
Methods
Polysaccharide nucleic acid fraction from BCG (BCG-
PSN) is an immuno-modulatory product extracted by hot
phenol method from BCG which is considered to be suc-
cessful clinical application in immune disorders or
immune levels decline and the treatment of allergic dis-
eases. In this study, we evaluated whether the BCG-PSN
could serve as a novel adjuvant of DNA vaccine to elicit
better cellular and humoral immune responses against the
HIV-1 Env antigen in Balb/c mice model. The BCG-PSN
was mixed with 10 μg, 30 μg, 100 μg of
pDRVI1.0gp1455M (HIV-1 CN54 gp145 gene) DNA vac-
cine and intramuscularly immunized two or three times.
Results
We found that BCG-PSN could significantly improve the
immunogenicity of DNA vaccine when administered
together with DNA vaccine. Further, we demonstrated
that at 100 μg dose, co-immunized twice with BCG-PSN
adjuvant elicited Env specific immune responses which
were comparable to those induced by three immuniza-
tions with DNA alone. At the same vaccination schedule,
BCG-PSN co-immunization with 30 μg DNA vaccine
could elicit cellular and humoral immune responses
which were comparable to that induced by 100 μg DNA
vaccine alone.
Conclusion
BCG-PSN can serve as a novel adjuvant for DNA vaccina-
tion.
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